Last reviewed · How we verify

NCT05686265: NOX2

Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage

Terminated Last updated 19 March 2024
What this trial tests

trial testing Oxygen in Subarachnoid Hemorrhage, Aneurysmal in 3 participants. Terminated before completion.

Timeline
11 May 2023
Primary endpoint
15 March 2024
15 March 2024

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusTerminated
Study typeOBSERVATIONAL
Enrollment3
Start date11 May 2023
Primary completion15 March 2024
Estimated completion15 March 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aneurysmal subarachnoid haemorrhage (SAH) carries a high morbidity and mortality, which is in part due to the development of secondary brain injury. The mechanisms behind this remain incompletely understood, but oxidative/nitrosative stress and disturbances in vasoregulatory mechanisms are believed to be involved. The present study aims to characterise the transcerebral exchange of oxidative/nitrosative stress markers and nitric oxide metabolites during the early phase after SAH compared to healthy volunteers, including the influence of induced changes in arteriel oxygen tension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Oxygen

Trials testing the same drug.

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05686265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing